A Dose Escalation Study of Bradanicline in Refractory Chronic Cough

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

November 5, 2018

Primary Completion Date

May 7, 2019

Study Completion Date

May 22, 2019

Conditions
Chronic Cough
Interventions
DRUG

Bradanicline

Three different doses over the course of the study

DRUG

Placebo

Matching placebo for Bradanicline

Trial Locations (17)

20854

Clinical Research of Gastonia, Gastonia

29420

National Allergy and Asthma Research, North Charleston

32789

Florida Pulmonary Research Institute, Winter Park

33872

Center for Cough, Largo

53228

Allery Asthma & Sinus Center, Greenfield

55441

Clinical Research Institute, Plymouth

55905

Mayo Clinic, Pulmonary Clinic Research Unit, Rochester

75231

AARA Research Center, Dallas

Pharmaceutical Research and Consulting, Inc., Dallas

78229

Diagnostics Research Group, San Antonio

80230

Colorado Allergy and Asthma Center, Denver

80907

Asthma and Allergy Associates, Colorado Springs

Storms Clinical Research Institute, Colorado Springs

91942

BioSolutions Clinical Research Center, La Mesa

92691

Allergy & Asthma Associates of Southern California, Mission Viejo

98225

Bellingham Asthma Allergy and Immunology Clinic, Bellingham

07712

Atlantic Research Center, LLC, Ocean Township

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Attenua, Inc.

INDUSTRY